Episurf’s implants approved for sale in Malaysia
Episurf Medical (NASDAQ: EPIS B) today announces that the Medical Device Authority (MDA) in Malaysia has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Malaysian market. The approval follows a review process.
“It is exciting to see the progress of the regulatory work for Episurf’s devices towards new markets. This regulatory approval opens up the market and enables us to work with our distributor towards the next important steps in Malaysia“, says Michael Näsström, Head of Quality and Regulatory Affairs at Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CET on 17 January 2022.
Tags: